Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease

References

• Allamneni C, Venkata K, Yun H, et al. Comparative effectiveness of vedolizumab vs. infliximab induction therapy in ulcerative colitis: experience of a real-world cohort at a Tertiary Inflammatory Bowel Disease Center. Gastroenterology Res. 2018;11(1):41–45.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as Induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7(4):289–300.
   PubMed Web of Science ®Google Scholar
• Mitrev N, IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group, Casteele NV, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11-12):1037–1053.
   PubMed Web of Science ®Google Scholar
• Singh S, Dulai PS, Casteele NV, et al. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019;50(8):848–857.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Rosario M, Lasch K, et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther. 2019;49(4):408–418.
   PubMed Web of Science ®Google Scholar
• Hanžel J, Sever N, Ferkolj I, et al. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United Eur Gastroenterol J. 2019;7(6):741–749.
   PubMed Web of Science ®Google Scholar
• Guidi L, Pugliese D, Tonucci TP, et al. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United Eur Gastroenterol J. 2019;7(9):1189–1197.
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Minsart C, Cremer A, et al. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Eur J Gastroenterol Hepatol. 2019;31(4):478–485.
   PubMed Web of Science ®Google Scholar
• Rosario M, Dirks NL, Milch C, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet. 2017;56(11):1287–1301.
   PubMed Web of Science ®Google Scholar
• Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin Gastroenterol Hepatol. 2017;15(11):1750–1757.
   PubMed Web of Science ®Google Scholar
• Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther. 2018;47(7):906–912.
   PubMed Web of Science ®Google Scholar
• Plevris N, Jenkinson PW, Chuah CS, et al. Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease. Frontline Gastroenterol. 2020;11(2):117–123.
   PubMed Web of Science ®Google Scholar
• Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(12):1937–1946.
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Yarur A, Jossen J, et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J Crohns Colitis. 2019;13(8):963–969.
   PubMed Web of Science ®Google Scholar
• Al-Bawardy B, Ramos GP, Willrich MAV, et al. Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(3):580–586.
   PubMed Web of Science ®Google Scholar
• Birdi S, Sierra MM, Samaan M, et al. Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease. Gut. 2018;67:A69–A70.
   PubMed Web of Science ®Google Scholar
• Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therap Adv Gastroenterol. 2018;11:1756284818772786.
   Web of Science ®Google Scholar
• Amiot A, OBSERV-IBD study group and the GETAID, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–321.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–1064.
   PubMed Web of Science ®Google Scholar
• Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113(9):1345.
   PubMed Web of Science ®Google Scholar
• Bye WA, Jairath V, Travis S. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3–15.
   PubMed Web of Science ®Google Scholar